VISIT BOOTH 36157 2024 ASCO® Annual Meeting
This site is intended for US healthcare professionals
See 3-YEAR follow-up data1

Dosing

hero imagehero image

KIMMTRAK is administered once weekly
via continuous IV infusion over 15-20 minutes
1,*

Adequate hydration/euvolemic status prior to starting KIMMTRAK is advised1

Please see AE management section for more detailed information.

KIMMTRAK begins with a step-up dose schedule designed to decrease the risk of adverse events.1

A KIMMTRAK dosing schedule chart that goes from week one to week four and beyondA KIMMTRAK dosing schedule chart that goes from week one to week four and beyond

The starting dose is 20 mcg for week 1. The dose increases to 30 mcg for week 2 and 68 mcg for week 3 and beyond.1

  • *In clinical trials, patients stopped treatment for disease progression, unless they were otherwise deriving benefit, or for unacceptable toxicity.1
  • If patient has not had a ≥ grade 2 cytokine release syndrome adverse event with their previous dose.1
  • If patient has not had hypotension requiring medical intervention with their most recent dose.1
  • §Adjustment in what to monitor and at what frequency can be made using clinical judgment or by institutional standards. Recommendations above based on clinical trial protocol.3
Treatment guide: dosing and AE monitoring and management

Treatment guide: dosing and AE monitoring and management

Download
Pharmacist dosing, preparation, and AE management guide

Pharmacist dosing, preparation, and AE management guide

Download
Pharmacist KIMMTRAK preparation video

Pharmacist KIMMTRAK preparation video

AE, adverse event.

Indication
 
Important Safety Information Including Boxed Warning

KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

WARNING: CYTOKINE RELEASE SYNDROME
Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated.

Indication and Important Safety Information Including Boxed Warning

Indication

KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Important Safety Information Including Boxed Warning

WARNING: CYTOKINE RELEASE SYNDROME
Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated.
Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending on persistence and severity of CRS.

Skin ReactionsSkin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.

Elevated Liver Enzymes Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.

Embryo-Fetal ToxicityKIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during treatment with KIMMTRAK and 1 week after the last dose.

The most common adverse reactions (≥30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting. The most common (≥50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased phosphate.

Please see full Prescribing Information, including BOXED WARNING for CRS.

References:
1. Kimmtrak. Package insert. Immunocore Ltd; 2022. 2. Data on file. Immunocore. [2024-C004]. 3. Nathan P, Hassel JC, Rutkowski P, et al; IMCgp100-202 Investigators. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196-1206. doi:10.1056/NEJMoa2103485